NCT02779569Unknown不适用
Prospective, Open, Multi-center, Double Arm Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
The First Affiliated Hospital with Nanjing Medical University6 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 80
- 试验地点
- 6
- 主要终点
- Grade III and IV hematologic toxicity, according to National Cancer Institute common toxicity criteria (NCI-CTC) V3.0 criteria
研究概览
简要总结
To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS
详细描述
To develop a highly effective and safe protocol, a multi-center, prospective clinical trial was conducted in China, with aims to evaluate the grade III and IV hematologic toxicity and clinical efficacy of subcutaneous injection of ultra-low-dose decitabine (5 to 7 mg/m2) for treatment of myelodysplastic syndrome (MDS), while decitabine at a dose of 20 mg/m2 as a control.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women aged 18 to 80 years;
- •Patients at high risk of MDS assessed by International Prostate Symptom Score (IPSS);
- •Chronic myelomonocytic leukemia (CMML) patients with abnormal white blood cell counts, extremely low platelet count or organ infiltration (such as hepatomegaly, splenomegaly) that required therapy;
- •Patients at low risk of MDS identified by IPSS score who had secondary MDS, platelet count of < 20*10^9/L, no response to erythropoietin (EPO) (non-5q deletion syndrome) in the presence of disease symptoms or blood transfusion dependence, or no response to EPO/lenalidomide (5q deletion syndrome) in the presence of disease symptoms or blood transfusion dependence;
- •Patients with a Eastern Cooperative Oncology Group (ECOG) of 0 to 2;
- •Patients with an expected lifespan of over 6 months;
- •Patients with a aspartate aminotransferase (AST) of < 2.5 times higher than the normal upper limit, alanine aminotransferase (ALT) of < 2.5 times higher than the normal upper limit, total bilirubin of < 1.5 times higher than the normal upper limit, and serum creatinine of < 1.5 times higher than the normal upper limit;
- •Subjects who had recovery of toxicity, did not undergo any therapy 4 weeks prior to the first trial, and did not receive nitrosourea therapy and bone marrow transplantation 6 weeks prior to the first trial;
- •Female subjects were menopausal, underwent surgical sterilization, or had effective contraception (oral contraceptive, injectable contraceptive, intrauterine device, contraceptive patch, male sterilization) prior to enrollment and during the trial, and were negative for serum or urine pregnancy test at screening;
- •No insemination was given to male subjects during the treatment and within 2 months post-treatment;
- •Subjects complying with the study protocol;
- •Subjects that signed the informed consent, which indicated they understood the purpose, the procedure and potential benefits of the trial and were willing to participate in the trial.
排除标准
- •Patients that were diagnosed as acute myeloid leukemia (primitive bone marrow cell proportion of 20% or higher) or other progressive malignant diseases;
- •Patients that received treatment with other drugs within 30 days prior to the first administration of decitabine;
- •Patients that received radiotherapy within 14 days prior to the first administration of decitabine;
- •Patients with uncontrolled heart disease or congestive heart failure;
- •Patients with uncontrolled restrictive or obstructive pulmonary disease;
- •Patients with active viral, bacterial or invasive fungal infections;
- •Patients that were complicated by autoimmune hemolytic anemia or immune thrombocytopenia;
- •Patients with a history of use of azacitidine or decitabine;
- •Patients that were sero-positive for HIV;
- •Patients with mental or other disorders that cannot completely cooperate with the treatment or follow up;
- •Patients bone marrow cannot be sampled;
- •Subjects that were allergic to decitabine vehicle;
- •Pregnant or lactating women.
研究组 & 干预措施
Ultra-low-dose group
Experimental
decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
干预措施: decitabine (Drug)
Low-dose group
Active Comparator
decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
干预措施: decitabine (Drug)
结局指标
主要结局
Grade III and IV hematologic toxicity, according to National Cancer Institute common toxicity criteria (NCI-CTC) V3.0 criteria
时间窗: 8 months
次要结局
- Hematologic improvement (HI), according to IWG response criteria(8 months)
- Partial response (PR) rate, according to IWG response criteria(8 months)
- Complete response, according to International Working Group (IWG) response criteria(8 months)
- Complete response (CR) rate of bone marrow, according to IWG response criteria(8 months)
- The quality of life, the quality of life will be assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30)(8 months)
- Overall response rate, defined as CR＋PR＋HI, according to IWG response criteria(8 months)
- Cytogenetic response, according to IWG response criteria(8 months)
- times of transfusion requirements(8 months)
- times of hospitalization(8 months)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
1 期
Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AMLAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT01277484Seoul St. Mary's Hospital19
Unknown
不适用
Study on the Therapeutic Effect of TCM Treatment for MDR MNIdiopathic Membranous NephropathyNCT02610595Shanghai University of Traditional Chinese Medicine220
招募中
2 期
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)Diabetic Kidney DiseaseNCT06006689Tasly Pharmaceutical Group Co., Ltd228
Unknown
4 期
A Phase Ⅳ Study of Decitabine in Myelodysplastic SyndromeMyelodysplastic SyndromeNCT02013102Cttq240
已完成
3 期
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01751867Xian-Janssen Pharmaceutical Ltd.135